Colo 205

LoVo, Colo-205, Caco-2, and Colon-26 cells were obtained from the Riken Cell Bank (Ibaraki, Japan) and maintained in RPMI-1640 medium (Sigma, St Louis, MO, USA) and fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) in the presence of 5% CO₂ at 37 °C. SW948 cells were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan) and maintained in L-15 medium (Sigma) supplemented with FBS (Gibco) in the presence of 5% CO₂ at 37 °C. HT-29 cells were purchased from DS Pharma Biomedical (Osaka, Japan) and maintained in McCoy’s 5a medium (Sigma) supplemented with FBS (Gibco) in the presence of 5% CO₂ and temperature at 37 °C. L-OHP was purchased from LC Laboratories (Woburn, MA, USA). Simvastatin and fluvastatin were obtained from FUJIFILM Wako (Tokyo, Japan).

DLD-1 cells were purchased from the Health Science Research Resources Bank (Osaka, Japan). LoVo, Colo-205 and Caco-2 cells were purchased from Riken Cell Bank (Ibaraki, Japan). HT-29 cells were purchased from DS Pharma Biomedical (Osaka, Japan). These cells were cultured in RPMI1640 medium (Sigma, St Louis, MO, USA), HamF12 medium (Sigma) or McCoy’s 5A medium (Sigma) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), 100 μg/mL penicillin (Gibco), 100 U/mL streptomycin (Gibco) and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4; FUJIFLIM Wako, Tokyo, Japan) in an atmosphere containing 5% CO₂.
LoVo and Colo-205 cells with acquired resistance to PD0325901 (LC Laboratories, Woburn, MA, USA) or trametinib (LC Laboratories) (LoVo/PR, Colo-205/PR and LoVo/TR) were generated as previously described [37 (link),51 (link),52 (link),53 (link),54 (link),55 (link)].